首页> Diabetes, obesity & metabolism> A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

导出原文传递

翻译打印收藏纠错

第一作者： Gantz, Ira

作者： Gantz, Ira ^[1] ; Okamoto, Taro ^[2] ; Ito, Yuka ; Okuyama, Kotoba ; O'Neill, Edward A. ; Kaufman, KeithD. ; Engel, Samuel S. ; Lai, Eseng

作者单位： Merck & Co Inc, Kenilworth, NJ USA ^[1] MSD KK, Tokyo, Japan ^[2]

关键词 incretins oral antihyperglycaemic agent MK-3102

发布时间 2018-05-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Diabetes, obesity & metabolism

2017年19卷11期

1602-1609页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Diabetes, obesity & metabolism

2017年19卷11期

1602-1609页

检索历史清除

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

Diabetes, obesity & metabolism

相似文献

同项目论文

Diabetes, obesity & metabolism

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes

Diabetes, obesity & metabolism

相似文献

同项目论文

Diabetes, obesity & metabolism

相关期刊

检索历史清除